A method for producing diglycerides is provided. The method includes combining (i) an oil comprising at least one polyunsaturated fatty acid in the form of ethyl esters, free fatty acids, and/or combinations thereof, (ii) lipase, and (iii) glycerol in water to produce diglycerides with a high level of purity. Highly pure diglycerides obtained according to the method are also provided.

The present invention relates to a compound isolated from Torilidis Fructus, and an anticancer pharmaceutical composition containing same as an active ingredient, wherein the compound of the present invention has effects of reducing the viability of various types of cancer cells, having no effect on the cell viability of normal cells and reducing the tumor size and weight of lung cancer and colorectal cancer when used in an animal model. Therefore, the compound according to the present invention can be usefully used in anticancer drugs or health functional food industries.

The present invention relates to a compound isolated from Torilidis Fructus, and an anticancer pharmaceutical composition containing same as an active ingredient, wherein the compound of the present invention has effects of reducing the viability of various types of cancer cells, having no effect on the cell viability of normal cells and reducing the tumor size and weight of lung cancer and colorectal cancer when used in an animal model. Therefore, the compound according to the present invention can be usefully used in anticancer drugs or health functional food industries.

A process for obtaining product streams enriched with polyol esters from the secondary streams from polyol ester preparation, comprising a) the reaction of polyols of the general formula (II)
H—(—O—[—CR.sup.1R.sup.2—].sub.m—).sub.o—OH  (II) in which R.sup.1 and R.sup.2 are each independently hydrogen, an alkyl radical having 1 to 5 carbon atoms or a hydroxyalkyl radical having 1 to 5 carbon atoms, m is an integer from 1 to 10, o is an integer from 2 to 15, with linear or branched aliphatic monocarboxylic acids having 3 to 20 carbon atom, with removal of the water formed; b) the removal of unconverted starting compounds from the crude ester formed; c) the treatment of the crude ester obtained in step b) with steam to form a volatile secondary stream; and d) the removal of the volatile secondary stream obtained in step c), characterized in that the volatile secondary stream obtained in step d) is separated into an aqueous phase and an organic phase and the organic phase removed is subjected to a further treatment with steam and a product stream enriched with polyol esters is obtained as residue.

A process for obtaining product streams enriched with polyol esters from the secondary streams from polyol ester preparation, comprising a) the reaction of polyols of the general formula (II)
H—(—O—[—CR.sup.1R.sup.2—].sub.m—).sub.o—OH  (II) in which R.sup.1 and R.sup.2 are each independently hydrogen, an alkyl radical having 1 to 5 carbon atoms or a hydroxyalkyl radical having 1 to 5 carbon atoms, m is an integer from 1 to 10, o is an integer from 2 to 15, with linear or branched aliphatic monocarboxylic acids having 3 to 20 carbon atom, with removal of the water formed; b) the removal of unconverted starting compounds from the crude ester formed; c) the treatment of the crude ester obtained in step b) with steam to form a volatile secondary stream; and d) the removal of the volatile secondary stream obtained in step c), characterized in that the volatile secondary stream obtained in step d) is separated into an aqueous phase and an organic phase and the organic phase removed is subjected to a further treatment with steam and a product stream enriched with polyol esters is obtained as residue.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes.

The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.